Rapamycin Exacerbates Staphylococcus aureus Pneumonia by Inhibiting mTOR-RPS6 in Macrophages
Fang-Yi Yu,Kua Zheng,Yin-Fang Wu,Shen-Wei Gao,Qing-Yu Weng,Chen Zhu,Yan-Ping Wu,Miao Li,Zhong-Nan Qin,Jia-Fei Lou,Zhi-Hua Chen,Song-Min Ying,Hua-Hao Shen,Wen Li
DOI: https://doi.org/10.2147/jir.s434483
IF: 4.5
2023-12-01
Journal of Inflammation Research
Abstract:Fang-Yi Yu, &ast Kua Zheng, &ast Yin-Fang Wu, &ast Shen-Wei Gao, Qing-Yu Weng, Chen Zhu, Yan-Ping Wu, Miao Li, Zhong-Nan Qin, Jia-Fei Lou, Zhi-Hua Chen, Song-Min Ying, Hua-Hao Shen, Wen Li Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen Li, Tel +86-571-87783729, Fax +86-571-87068001, Email Purpose: This study aimed to explore the effect of Rapamycin (Rapa) in Staphylococcus aureus ( S. aureus ) pneumonia and clarify its possible mechanism. Methods: We investigated the effects of Rapa on S. aureus pneumonia in mouse models and in macrophages cultured in vitro. Two possible mechanisms were investigated: the mTOR-RPS6 pathway phosphorylation and phagocytosis. Furthermore, for the mechanism verification in vivo, mice with specific Mtor knockout in myeloid cells were constructed for pneumonia models. Results: Rapa exacerbated S. aureus pneumonia in mouse models, promoting chemokines secretion and inflammatory cells infiltration in lung. In vitro, Rapa upregulated the secretion of chemokines and cytokines in macrophages induced by S. aureus . Mechanistically, the mTOR-ribosomal protein S6 (RPS6) pathway in macrophages was phosphorylated in response to S. aureus infection, and the inhibition of RPS6 phosphorylation upregulated the inflammation level. However, Rapa did not increase the phagocytic activity. Accordingly, mice with specific Mtor knockout in myeloid cells experienced more severe S. aureus pneumonia. Conclusion: Rapa exacerbates S. aureus pneumonia by increasing the inflammatory levels of macrophages. Inhibition of mTOR-RPS6 pathway upregulates the expression of cytokines and chemokines in macrophages, thus increases inflammatory cells infiltration and exacerbates tissue damage. Keywords: Staphylococcus aureus , pneumonia, macrophage, rapamycin, mTOR- ribosomal protein S6 signaling pathway Staphylococcus aureus ( S. aureus ), one of the most infamous and widespread bacterial pathogens in hospitals and communities, causes millions of severe invasive infections each year. 1–3 Approximately 20–40% of the population asymptomatically harbor S. aureus colonization in the nasal squamous epithelium. 3,4 As an opportunistic pathogen, immunocompromised patients, such as those using immunosuppressants, are at a greater risk of infection. 5,6 Macrophages are important innate immune cells and serve as the first line of defense against pathogenic infections through phagocytosis and chemokine secretion, in addition to the role played by skin barrier. 7 However, bacterial lipoproteins (LPPs) in Gram-positive bacteria, particularly S. aureus , can induce multiple distinct cellular states in macrophages, and these inflammatory trajectories change as the infection persists. 6,8 These characteristics bring about significant complexities in researches and treatments. Rapamycin (Rapa) is an immunosuppressive and antitumor drug. 1,9 It is now commonly used in the clinic to combat rejection after organ transplantation and to resist tumor progression. 10–14 Despite its beneficial effects, Rapa is reported to cause pneumonitis, such as non-infectious alveolitis and interstitial pneumonitis with inflammatory cells infiltration. 15 In addition to non-infectious pneumonia, 16 opportunistic infectious pneumonia is also well-reported in immunosuppressed state. In patients undergoing hematopoietic stem cell transplant (HSCT), who are in typical immunosuppressed states, pneumonia is reported to be the second most common nosocomial infection. 17 Bacterial is the leading cause of microorganism-caused pneumonia in HSCT patients and accounts for 44.4%. 18 Among them, S. aureus is one of the most common pathogens and is usually associated with multidrug-resistant (MDR) characteristics. 19 It has also been pointed out that immunosuppression can worsen mortality in cases of ventilator-associated pneumonia (VAP). 20 These facts prompt us to be vigilant about the impact of immunosuppressant use on S. aureus pneumonia. Rapa inhibits its target, mTOR, a protein complex composed of three components. The catalytic subunit of mTOR is a serine/threonine protein kinase that can be activated through phosphorylation. 21–24 mTOR is a crucial receptor in cell growth and metabolism, pla -Abstract Truncated-
immunology